← Back to Search

Central Nervous System Stimulant

Treatment for Attention Deficit Hyperactivity Disorder (ADHD) (MYDAYIS Trial)

Phase 3
Waitlist Available
Led By Leonard Adler, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 7
Awards & highlights

MYDAYIS Trial Summary

This study is evaluating whether a drug may help improve attention and hyperactivity for individuals with ADHD.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

MYDAYIS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 7
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 7 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Mydayis Treatment
Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In
Secondary outcome measures
14-Hour Post-Dose Time-Sensitive Adult ADHD Symptom Scale (TASS) Score at End of Mydayis Treatment
14-Hour Post-Dose Time-Sensitive Adult ADHD Symptom Scale (TASS) Score at End of Placebo Lead-In
14-hour Post-Dose TASS: Hyperactive-Impulsive (HI) Symptom Subscale Score at End of Mydayis Treatment
+61 more

MYDAYIS Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment2 Interventions
After a two-week, single-blinded, placebo lead-in, all patients will receive four weeks of order-fixed treatment with Mydayis.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MYDAYIS
2020
Completed Phase 3
~60
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,367 Previous Clinical Trials
839,709 Total Patients Enrolled
12 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
678 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Leonard Adler, MDPrincipal InvestigatorNew York Langone Medical Center
Lenard Adler, MDPrincipal InvestigatorNew York Langone Medical Center
4 Previous Clinical Trials
138 Total Patients Enrolled
3 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
120 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Michigan
Pennsylvania
South Carolina
How old are they?
18 - 65
What site did they apply to?
New York University School of Medicine
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Email
Most responsive sites:
  1. New York University School of Medicine: < 48 hours
Recent research and studies
clinicaltrials.govStudy
Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
2020. "Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03945175.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top